深度学习评估吸烟者肺气肿与纤维化间质性肺异常的进展
本研究基于COPDGene研究中4,450名吸烟者基线和5年随访CT,用深度学习算法评估肺气肿和肺纤维化的进展。纤维化最小临床重要差值为0.58%。肺气肿和纤维化同时进展者死亡风险显著增加(HR 2.18)。
要点
- 纤维化进展的最小临床重要差值为0.58%肺容积。
- 肺气肿和纤维化同时进展者死亡风险最高(HR 2.18)。
- 单纯肺气肿或纤维化进展也增加死亡风险。
核心结论
- 在无已知间质性肺病的吸烟者中,纤维化的微小变化可能具有临床意义。
- 肺气肿和纤维化同时进展与死亡率增加相关。
研究设计与样本
- 基于COPDGene研究中4,450名吸烟者的基线和5年随访CT扫描。
- 使用深度学习算法评估肺气肿和肺纤维化。
- 采用混合分布和锚定法确定纤维化的最小临床重要差值。
- 使用多变量共享脆弱模型(年龄时间尺度)评估进展与死亡率的关系。
主要发现
- 纤维化的最小临床重要差值为0.58%。
- 2,822名(63%)参与者既无肺气肿也无纤维化进展。
- 841名(19%)仅有肺气肿进展,512名(12%)仅有纤维化进展,275名(6.2%)两者均进展。
- 与无进展者相比,肺气肿进展者的死亡风险比为1.42(95%CI 1.11-1.82)。
- 纤维化进展者的死亡风险比为1.49(95%CI 1.14-1.94),两者均进展者为2.18(95%CI 1.58-3.02)。
关键数值与推荐
- 肺气肿进展定义为等级增加至少一级(等级:无、微量、轻度、中度、融合、晚期破坏性)。
- 纤维化以肺容积百分比表示,最小临床重要差值为0.58%。
临床怎么用
- 对于无已知间质性肺病的吸烟者,应关注肺气肿和纤维化的进展。
- 纤维化微小变化(≥0.58%)可能具有临床意义,需密切随访。
- 肺气肿和纤维化同时进展者死亡风险最高,应加强管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Although studies have evaluated emphysema and fibrotic interstitial lung abnormality individually, less is known about their combined progression. Objectives: To define clinically meaningful progression of fibrotic interstitial lung abnormality in smokers without interstitial lung disease and evaluate the effects of fibrosis and emphysema progression on mortality. Methods: Emphysema and pulmonary fibrosis were assessed on the basis of baseline and 5-year follow-up computed tomography scans of 4,450 smokers in the COPDGene Study using deep learning algorithms. Emphysema was classified as absent, trace, mild, moderate, confluent, or advanced destructive. Fibrosis was expressed as a percentage of lung volume. Emphysema progression was defined as an increase by at least one grade. A hybrid distribution and anchor-based method was used to determine the minimal clinically important difference in fibrosis. The relationship between progression and mortality was evaluated using multivariable shared frailty models using an age timescale. Measurements and Main Results: The minimal clinically important difference for fibrosis was 0.58%. On the basis of this threshold, 2,822 (63%) had progression of neither emphysema nor fibrosis, 841 (19%) had emphysema progression alone, 512 (12%) had fibrosis progression alone, and 275 (6.2%) had progression of both. Compared with nonprogressors, hazard ratios for mortality were 1.42 (95% confidence interval, 1.11-1.82) in emphysema progressors, 1.49 (1.14-1.94) in fibrosis progressors, and 2.18 (1.58-3.02) in those with progression of both emphysema and fibrosis. Conclusions: In smokers without known interstitial lung disease, small changes in fibrosis may be clinically significant, and combined progression of emphysema and fibrosis is associated with increased mortality.
引用
- Ash SY, Choi B, Oh A, et al. Deep Learning Assessment of Progression of Emphysema and Fibrotic Interstitial Lung Abnormality. Am J Respir Crit Care Med. 2023. PMID: 37364281. doi:10.1164/rccm.202211-2098OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。